EuBiologics (206650) Fundamentals 2026 — P/E 9.5x, Revenue Analysis | SniperIQ
EuBiologics (206650) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩279.8B, trading at ₩7620.00 on the KOE. This SniperIQ fundamentals page covers EuBiologics's valuation (P/E 9.5x, P/B 1.6x), profitability (net margin 23.3%), revenue (₩149.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is EuBiologics's market cap?
EuBiologics (206650) has a market capitalization of approximately ₩279.8B, trading at ₩7620.00 on the KOE. Market cap moves with the live share price.
What is EuBiologics's P/E ratio?
EuBiologics's trailing twelve-month P/E ratio is 9.5x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is EuBiologics?
EuBiologics runs a net profit margin of 23.3%, a gross margin of 57.7%, and an operating margin of 36.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does EuBiologics generate?
EuBiologics reported revenue of ₩149.2B for fiscal year 2025, with net income of ₩41.3B and earnings per share (EPS) of 1127.16. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does EuBiologics pay a dividend?
EuBiologics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is EuBiologics financially healthy?
EuBiologics carries a debt-to-equity ratio of 0.00x and a current ratio of 3.99x, with a market beta of 0.19. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is EuBiologics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For EuBiologics (206650) the key facts are: market cap ₩279.8B, P/E 9.5x, revenue ₩149.2B, 52-week range 7450-17700. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track EuBiologics's full fundamentals live
Get EuBiologics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.